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Peritoneal transfer of kanamycin and its use in peritoneal
dialysis. The effect of kanamycin administration on 15 func-
tionally anephric chronic renal failure patients undergoing
maintenance peritoneal dialysis was studied. Following intra-
muscular administration of kanamycin (7 mg/kg body wt),
peritoneal dialysis of 22 hr removed 32% of the injected dose.
The mean kanamycin peritoneal clearance was 8.3 mI/mm
compared to a crcatinine peritoneal clearance of 17.7 mI/mm.
Peritoneal dialysis reduced the serum half-life of kanamycin
from 84 to 12 hr. If an anuric patient receiving kanamycin therapy
is undergoing peritoneal dialysis, then additional kanamycin
amounting to about 3.5 mg/kg body wt for each day of peritoneal
dialysis must be given to compensate for dialysis removal.
However, compensation is more easily obtained by adding
kanamycin to the inflow peritoneal dialysate. It reaches a
therapeutic serum concentration following ten hr of dialysis
and maintains a state of equilibrium after 16 hr, with the serum
level approximately 50% of the dialysate inflow concentration.
Thus a serum level can be maintained by adding twice the desired
serum concentration to the pcritoneal dialysate. In most cases
addition of 20 mg of kanamycin to each liter of inflow dialysate
is recommended.
Le transfert péritonéal de Ia kanamycine et son emploi dans Ia
dialyse péritonéale. L'effet de l'administration de kanamycine
a 15 sujets fonctionnellement anéphriques et soumis a des dialyses
péritonéales itératives a été étudié. Après une injection intra-
musculaire de kanamycine (7 mg/kg) une dialyse péritonéale de
22 heures soustrait 32% de Ia dose injectée. La clearance pen-
tonéale moyenne de Ia kanamycine est dc 8,3 mI/mm quand Ia
clearance penitoneale de la créatinine est de 17,7 mI/mm. La
dialyse péritonéale réduit Ia demi-vie sénique de Ia kanamycine
de 84 a l2houres. Si un malade anurique qui reçoit de Ia kanamy-
cine est soumis a une dialyse pénitonéale, un supplement de
kanamycine doit étre donné pour compenser Ia soustraction par
la dialyse. Ce supplement est d'environ 3,5 mg/kg de poids
corporel pour chaque jour de dialyse péritonéale. La compensa-
tion est cependant plus facilement réalisée par l'addition de
kanamycine au liquide de dialyse entrant. La concentration
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sérique therapeutique est alors atteinte aprés 10 heures de dialyse
et se maintient a l'équilibre aprés 16 heures, elle atteint 50% de
Ia concentration dans Ic liquide de dialyse entrant. Ainsi une
concentration sérique peut-elle être maintenue quand Ia con-
centration dans Ic liquide de dialyse en est Ic double. Dans Ia
plupart des cas l'addition de 20 mg de kanamycine a chaque litre
de liquide entrant est préconisée.
Peritoneal dialysis is now widely used in treatment of
renal failure. Infection is frequently seen in these severely
ill patients and it demands prompt and powerful anti-
biotic therapy. Kanamycin can be an especially useful
broad spectrum antibiotic for this clinical setting. However,
because of potentially serious effects of overdosage, serum
levels are needed which are effective yet safe. Such a
rational therapeutic approach in these patients requires
an accurate knowledge of kanamycin peritoneal transfer,
but at this time little is known about the effect of peritoneal
dialysis on antibiotic dosage schedules [1—8], including
kanamycin [6, 8].
This study investigates kanamycin administration in
anuric patients undergoing maintenance peritoneal dialysis,
defines the kinetics of peritoneal kanamycin transfer, and
determines guidelines for kanamycin use in patients under-
going peritoneal dialysis.
Methods
Fifteen patients, aged 17 to 47 years, undergoing
maintenance peritoneal dialysis for end-stage renal disease,
were studied. Their mean creatinine clearance was 2.6 ml!
min/1.73 m2 (range: 0 to 6.7). No patient was clinically
septic, none had peritonitis, and none had received any
antibiotic in the previous three weeks.
The duration of maintenance dialysis in individual
patients ranged from 0 to 12 months (average: 3.9 months),
with an average of 8 dialyses (range: 0 to 39) prior to study.
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All patients were clinically edema-free at the time of study.
Patients lost an average of 2.6 kg of weight (range: —4 to
+ 0.9) during dialysis, and the mean outflow volume
exceeded the mean inflow volume by 1.0 liter (range:
—4.2 to + 2.5).
Peritoneal dialysis was performed with the repeated
puncture technique [9]. Exchanges were of 2 liters with an
over-all average dialysate rate of 3.5 liters/hr (range: 2.1 to
4.5) for the 22 hr of dialysis. Dialysate was standard
dialysis fluid (Formular 1 Biosedia Laboratory, Malakoff)
to which was added 400 U heparin/liter.
Inflow dialysate samples for kanamycin estimation were
taken from random sampling. Outflow dialysate aliquots
were obtained from the total outflow for each study period,
rather than random sampling, to ensure accuracy.
Kanamyciri concentration was determined with a disc-
sensitivity method modified from Grove and Randel [10]
using Bacillus subtilis (ATCC 6633) as the test organism.
Each individual determination was calculated from the
mean of five zones of inhibition. For each assay the serum
standard was made up and diluted in the patient's own
serum taken prior to kanamycin injection. Standards for
outflow dialysate were prepared in postdialysis dialysate.
This was found necessary because of changes in pH and
protein content in the dialysate, as it passed through the
peritoneal cavity.
Initial experiments showed that deterioration in kana-
mycin activity occurred in both pre- and postdialysate at
room temperature (18° C). This amounted to 13% de-
activation at six hr, 18% at 12 hr, 27% at 18 hr and 29%
at 24 hr in kanamycin added to fresh dialysate. For post-
dialysis dialysate the deterioration in kanamycin activity
was less rapid: 5% atsixhr, 10% at l2hr,12% at 18 hr and
20% after 24 hr. Accordingly, kanamycin was added to the
predialysis dialysate immediately before use. To avoid
errors due to drug decomposition the 22 hr outflow was
divided into five collection periods, and the kanamycin
concentration determined for each outflow period. The
longest period of outflow dialysate collection was seven hr
and deterioration of the kanamycin activity at this time
was within the total experimental limits of accuracy
(estimated at 15%). Samples from each individual patient
were stored at —20° C and assayed at one time.
Two studies were performed.
Study I. Kanamycin removal by peritoneal dialysis following
i.m. administration
Experiment I a. Kanamycin, (kanamycin sulphate) at a
dose of 7 mg/kg body wt was given by intramuscular
injection (average dose: 345 mg; range: 250 to 430 mg)
2 hr prior to commencement of peritoneal dialysis in
ten patients. After two hr this dose of kanamycin was
distributed throughout the extracellular space and achieved
an adequate serum level [11, 12]. Serum samples were
taken at the commencement, and at two, four, ten, 16, and
22 hr (the completion) of dialysis. Corresponding dialysate
outflow collections were made (periods of two, two, six,
six, and six hr).
The serum half-life of kanamycin both on and off dialysis
was determined from multiple serum concentrations by the
method of least squares [13]. Kanamycin peritoneal
clearance (CK) was calculated for each dialysis period, by
D
the formula CK = x V, where D is dialysate outflow
concentration, S the midpoint kanamycin serum concentra-
tion for that period (i.e., the geometric mean of the serum
level at beginning and end of the period) and V the volume
of dialysate outflow in mI/mm for that period. Concurrent
urea and creatinine clearances were also determined.
Experiment lb. Experiments on four patients compared
the peritoneal to blood diffusion characteristics of kana-
mycin, urea, and creatinine. Following an i.m. injection
of 7 mg/kg body wt of kanamycin two hr earlier, one liter
of dialysate was run into the peritoneal cavity. Samples of
blood and dialysate were obtained at 30 mm intervals for
four hr. The diffusion concentration ratio compares the
dialysate and serum concentrations.
Study 2. Intraperitoneal kanamycin administration during
peritoneal dialysis
Experiment 2a. Kanamycin was added to the inflow
dialysate in a concentration of approximately 15.0 jig/mI
(range: 14.4 to 18.5) in seven patients. Serum and dialysate
samples were taken for the same periods as in Experi-
ment Ia.
Experiment 2 b. The peritoneal absorption characteristics
of kanamycin were determined in four patients. One liter
of dialysate containing 7 mg kanamycin/kg body wt was
introduced into the patient's peritoneal cavity and half-
hour serum and dialysate kanamycin concentrations were
determined for four hr. The absorption concentration ratio
was the serum concentration of kanamycin as compared
with the dialysate concentration.
Results
Study 1. Kanamycin removal by peritoneal dialysis following
i.m. kanamycin
Experiment 1 a. The serum kanamycin half-life averaged
12.! hr (range: 8 to 17.5 hr) for 11 patients during peritoneal
dialysis but was prolonged to an average of 84.2 hr (range:
52 to 114 hr) for six of these patients when off dialysis.
Fig. I graphs the mean kanamycin serum level of ten
patients throughout peritoneal dialysis given 7 mg/kg body
wt of kanamycin i.m. two hr before commencement of
dialysis. The mean kanamycin serum concentration at the
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Fig. 1. The serum kanamycin concentration (ig/m1) during
peritoneal dialysis is shown following i.m. injection of 7mg/kg
body wt of kanamycin two hr before dialysis. Each point represents
the mean of ten patients. Horizontal bars show the maximum
and minimum serum concentrations of the ten patients averaged.
Two hours after i.m. kanamycin the mean serum level was
18.5 ig/ml. This fell to 10.5 jig/mI after ten hr of dialysis and to
an average of 4.8 jig/mI at the end of 22 hr of dialysis.
beginning of dialysis was 18.5; it fell to 10.5 jig/mI after
ten hr and to 4.8 jtg/ml at the end of 22 hr of dialysis.
The kanamycin removed by the peritoneal dialysis was
quantitated in ten patients. During the first period of
dialysis the mean kanamycin removal rate was 2.2 mg/liter
or 8.4 mg/hr. Over the final six hr of dialysis 0.8 mg of
kanamycin were removed for each liter of dialysate at
a rate of 2.8 mg/hour. Table I details kanamycin removal
during the total dialysis. It occurred at a rate of 4.8 mg/hr
and it amounted to 1.3 mg of kanamycin in each liter of
outflow dialysate. A total of 107.5 mg of kanamycin was
removed by the entire peritoneal dialysis. This represented
31.6% of the average injected dose.
The average kanamycin, urea, and creatinine peritoneal
clearances for all ten patients are listed in Table 1. The
over-all mean kanamycin peritoneal clearance was 8.3 ml/
mm. The mean urea clearance was 23.6 mI/mm; that for
Table 1. Mean peritoneal kanamycin removal and clearance in
ten anuric patients undergoing peritoneal dialysis following
i.m. kanamycin
Observation Total dialysis a
Duration of dialysis, hr 22.1 (15.2—24.7)
Volume of outflow dialysate, liters 79.7 (53.3—94.7)
Kanamycin removed, mg/liter 1.3
Removal rate, mg/hr 4.8
Total kanamycin removed, mg 107.5 (73.9—147.9)
% of injected dose removed 31.6 (23.9—41.1)
Kanamycin clearance, ml/min 8.3 (5.7—11.2)
Urea clearance, ml/min 23.6 (18.8—32.2)
Creatinine clearance, ml/min 17.7 (11.6—24.1)
a Each figure represents the mean of ten patients, each averaged
for five consecutive periods of dialysate collection. Minimum
and maximum values are in parentheses.
Fig. 2. The effect of the peritoneal dialysate flow rate on the
peritoneal clearance of urea and kanamycin. The average number
of determinations at each dialysate flow rate is shown. Horizontal
bars represent the maximum and minimum clearance values at
each point. . = kanamycin; 0 = urea. Optimal kanamycin
clearance occurs at a dialysate flow rate of 3 to 4.5 liters/hr.
Kanamycin clearance is about one-third that of the concurrent
urea clearance.
creatinine was 17.7 mI/mm. Thus peritoneal dialysis was
able to remove kanamycin from the body at 35% of the
efficiency of urea removal.
Fig. 2 graphs the effect of dialysate flow rate on the
clearance of urea and kanamycin. For optimal kanamycin
clearance a dialysate flow rate of between 3 and 4.5 liters/hr
is required. Below a dialysate flow rate of 2.5 liters/hr
(although the determinations were few) kanamycin clearance
is less. The graph also illustrates that kanamycin clearance
is about one third that of urea clearance at the various
dialysate flow rates studied.
Experiment 1 b. The kanamycin diffusion concentration
ratio (i.e., kanamycin dialysate concentration/kanamycin
serum concentration) is 24 % at one-half hr, 44 % at one hr,
68 % at two hr and 80% at four hr. Urea reaches a steady
state relationship between the dialysate and the serum after
one and one-half hr of diffusion, creatinine about two and
one-half hr and kanamycin at three hr.
Study 2. Intraperitoneal kanamycin administration during
peritoneal dialysis
Experiment 2a. Table 2 details the mean kanamycin
absorption rate and serum levels during each period of
dialysis for seven patients. During the first two hr of
dialysis an average of 6.6 mg kanamycin was absorbed
from each liter of inflow dialysate. This was a rate of
22.2 mg/hr. During this time the serum kanamycin reached
a concentration of 1.2 jig/ml or 7.8% of the inflow dialysate
level. In the final six hr of dialysis (collection period five)
4.5 mg kanamycin/liter of inflow dialysate was absorbed at
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Table 2. Mean peritoneal kanamycin absorption and serum concentration in seven patients during five consecutive collection periods
with the dialysate containing 15 ig/ml kanamycin
Observation
Dialysate collection period
5 Total dialysis1 2 3 4
Average duration of collection period, hr 2.3a 2.2 6.4 6.5 6.0 23.4
(17.7—24.8)
Average volume of outflow dialysate
for period, liters
6.1 6.2 15.8 17.6 16.2 61.9
(36.4—80.2)
Kanamycin absorption, mg/liter 6.6 7.4 6.0 6.1 4.5 5.9
Kanamycin absorption rate, mg/hour 22.2 22.5 15.0 16.9 13.3 15.7
Total kanamycin absorbed, my 49 50 95 108 65 367
(187—540)
Serum concentration at end of period,
pg/mi
1.2 2.1 4.2 6.1 6.7 —
Kanamycin serum level as 0/ of inflow
dialysate concentration
7.8 13.6 27.6 39.4 44.0 —
a Each figure represents the mean of seven patients with maximum and minimum values in parentheses.
a rate of 13.3 mg each hour. The serum kanamycin at the
end of dialysis averaged 6.7 ig/liter, 44% of the inflow
dialysate concentration.
There was little increase in serum kanamycin concentra-
tion over the final six hr period of dialysis when a mean
total of 65 mg of kanamycin was absorbed from the
dialysate (Fig. 3). A state of near equilibrium had been
reached between the serum and intraperitoneal kanamycin.
At equilibrium the amount of kanamycin absorbed over
the six hr period would represent the rate of systemic
deactivation or degradation of kanamycin in a patient with
a steady serum level of 7 jig/mI.
Over the whole period of dialysis (average duration:
23.4 hr), a mean total of 367 mg of kanamycin was absorbed
across the peritoneum. This amounted to 5.9 mg from each
liter of inflow dialysate or a rate of 15.7 mg of kanamy-
cm/hr.
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Fig. 3. Serum kanamycin concentrations during peritoneal dialysis
(PD.) with the inflow dialysate containing 15 pg/mi of kanamycin.
Each point represents a mean of seven patients with the horizontal
bars the maximum and minimum serum values. Serum kanamycin
increases steadily to a value of 6.1 jig/mI after 16 hr of dialysis
and then remains relatively constant with a mean serum con-
centration of 6.7 jig/mI at the finish of dialysis.
Experiment 2b. The percentage absorption concentration
ratio (serum kanamycin concentration/intraperitoneal con-
centration) after two hr of absorption was only 16%. After
four hr the serum concentration leveled out at 40% of the
intraperitoneal dialysate concentration.
Discussion
The study has demonstrated the relative ease with which
kanamycin crosses the peritoneal membrane. Peritoneal
dialysis reduces the kanamycin serum half-life from 84 to
12 hr in functionally anephric patients and actually removes
one-third of the injected dose of kanamycin during one
day of dialysis. Peritoneal dialysis is thus an effective
treatment of kanamycin overdosage, as has been previously
suggested [6, 14]. Our clearance data have shown that
peritoneal kanamycin clearance is optimal at a dialysate
flow rate of between 3 and 4.5 liters/hr and should be used
in cases of overdosage.
However, since a significant amount of kanamycin is
removed by peritoneal dialysis, patients receiving kanamycin
while undergoing dialysis need more of the drug than would
ordinarily be required by anuric patients. The usual dosage
schedules for anuric patients have recommended an initial
dose of I g followed by subsequent doses of 500 mg every
96 hr [15]. Recently a more exact approach has recom-
mended a dose of 7 mg/kg body wt, a dose which gives an
adequate serum concentration for an entire treatment
period in anuric patients [121. Our studies have shown that
one day of peritoneal dialysis removes about 30 % of an
injected dose of kanamycin. This amounts to 4.8 mg of
kanamycin/hr, a figure which confirms the observations
of Greenberg and Sanford who found 4.4 mg of kanamycin
to be removed by peritoneal dialysis each hour [6]. Thus,
based on removal figures alone, 115 mg (30 % of injected
dose) needs to be replaced daily during peritoneal dialysis.
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This corresponds to 2.5 mg/kg body wt of kanamycin
daily to compensate for dialysis removal.
An alternative way to determine the needed compensation
would be to base the administration of kanamycin on the
serum half-life during dialysis according to the Cutler-
Orme regimen for renal impairment [12]. Thus 7 mg/kg
body wt of kanamycin would be given each third half-life.
Since the average serum half-life of kanamycin in patients
undergoing peritoneal dialysis was 12 hr, then 7 mg/kg
body wt of kanamycin should be given every 36 hr of
dialysis, a dosage which corresponds to about 4.5 mg/kg
body wt of i.m. kanamycin each dialysis day. For an
average patient (50 kg) this would be equivalent to 225 mg
of kanamycin for each day of dialysis. This 225 mg includes
the 115 mg removed by the dialysis and an amount cor-
responding to the body's intrinsic capacity to deactivate or
degrade the drug.
Normally, kanamyein is entirely excreted by the kidney
and its metabolic degradation is insignificant [11]. However,
there must be some alternative pathway for metabolic
degradation, deactivation, or elimination as evidenced by
the gradual loss of kanamycin activity in the serum of
functionally anephrie patients. The amount of this meta-
bolic degradation is determined in Experiment 2a, where
equilibrium was approached over the final six hr of dialysis
between serum and inflow dialysate concentration. The
amount absorbed during this period (65 mg) is the maxi-
mum quantity of kanamycin required to maintain a rela-
tively constant serum concentration of about 7 pg/ml and
reflects the amount of systemic degradation of the drug
during this time.
Probably an easier and more exact mode of dosage
compensation is to add kanamycin to the peritoneal
dialysate. Study 2 showed that significant absorption from
dialysate containing kanamyein takes place. This has been
demonstrated for other antibiotics [1, 3, 4, 5, 7] as well as
kanamyein [8]. After 16 hr of dialysis the serum kanamycin
concentration stabilizes at approximately 45% of the
dialysis inflow level. The four hr absorption study also
equilibrated with the serum concentration at about 40%
of the dialysate kanamycin concentration. Since there seems
to be no active peritoneal transport process, the serum
concentration of kanamyein can never increase above the
peritoneal dialysate concentration. Thus toxic serum levels
can always be avoided while maintaining a constant and
effective serum concentration. Such an optimal serum
kanamycin concentration can be maintained during pen-
toneal dialysis by addition of twice the desired serum
concentration to the dialysate. In practice, a dialysate
concentration of kanamycin of 15 to 20 jig/mI (i.e., 15 to
20 mg/liter) is recommended.
To avoid intramuscular injections, kanamycin can be
given entirely in the dialysate. However, our study demon-
strated that adequate serum levels are not attained for at
least ten hr. Buck and Cohen also found after 12 hr of
peritoneal dialysis with the dialysate containing an average
of 20.7 jig/mI of kanamycin that serum levels reached only
5.6 jig/ml [8]. Therefore if a high serum concentration is
required rapidly an initial i.m. injection of 7 mg/kg body wt
of kanamycin should be given as a loading dose followed
by a sustaining administration in the dialysis fluid of 15 to
20 jig/mI.
The intraperitoneal administration of antibiotics in the
dialysate may also be beneficial for the treatment of
peritonitis [1, 8, 16—19]. Here, organisms in the peritoneal
cavity will be exposed to very high concentrations of anti-
biotic while adequate yet nontoxie levels are maintained in
the blood. Such a benefieal differential concentration of
antibiotic cannot be achieved by other means of admini-
stration. With an inflamed peritoneal membrane it might
be expected that the rate of kanamycin absorption could
be increased and therapeutic serum levels would be reached
more rapidly.
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